Aclarubicin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Aclarubicin
Aclarubicin.svg
Systematic (IUPAC) name
(1S,2S,4R)-Methyl 4-(((2S,5R,6R)-4-(dimethylamino)-5-(((1S,3R,4S)-3-hydroxy-5-methyl-4-(((2S,6R)-6-methyl-5-oxotetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
IV
Legal status
Legal status
  • ℞ (Prescription only)
Identifiers
CAS Number 57576-44-0 N
ATC code L01DB04 (WHO)
PubChem CID 42474
ChemSpider 1931 YesY
UNII 74KXF8I502 YesY
KEGG D02756 YesY
ChEBI CHEBI:74619 N
ChEMBL CHEMBL502620 N
Chemical data
Formula C42H53NO15
Molar mass 811.86 g/mol
 NYesY (what is this?)  (verify)

Aclarubicin (INN) or aclacinomycin A[1] is an anthracycline drug[2] that is used in the treatment of cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin. It can induce histone eviction from chromatin upon intercalation.[3][4]


References[edit]

  1. ^ CID 451415 from PubChem
  2. ^ Jensen PB, Jensen PS, Demant EJ, et al. (October 1991). "Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II". Cancer Res. 51 (19): 5093–9. PMID 1655244. 
  3. ^ Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J (2013). "Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin". Nature Communications 4: 1908. doi:10.1038/ncomms2921. PMID 23715267. 
  4. ^ Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J (2015). "Chemical profiling of the genome with anti-cancer drugs defines target specificities". Nature Chemical Biology 11 (7): 472. doi:10.1038/nchembio.1811. PMID 25961671.